Home > Full Text Reviews > The Effectiveness and Cost-Effectiveness... > Mixed-treatment comparisons performed in...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Bond M, Rogers G, Peters J, et al. The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model. Southampton (UK): NIHR Journals Library; 2012 Apr. (Health Technology Assessment, No. 16.21.)

Appendix 9Mixed-treatment comparisons performed in specified measurement populations

Cognitive

Alzheimer's Disease Assessment Scale – cognitive subscale

TABLE 148. Mixed-treatment comparison – ADAS-cog at 12–16 weeks (mean change from baseline; LOCF data only): input data

TABLE 149. Mixed-treatment comparison – ADAS-cog at 12–16 weeks (mean change from baseline; LOCF data only): results

TABLE 150. Mixed-treatment comparison – ADAS-cog at 12–26 weeks (mean change from baseline; classic ITT or LOCF data): input data

TABLE 151. Mixed-treatment comparison – ADAS-cog at 12–26 weeks (mean change from baseline; classic ITT or LOCF data): results

TABLE 152. Mixed-treatment comparison – ADAS-cog at 12–16 weeks (mean change from baseline; OC populations only): input data

TABLE 153. Mixed-treatment comparison – ADAS-cog at 12–16 weeks (mean change from baseline; OC populations only): results

TABLE 154. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; LOCF data only): input data

TABLE 155. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; LOCF data only): results

TABLE 156. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; classic ITT + LOCF data): input data

TABLE 157. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; classic ITT + LOCF data): results

TABLE 158. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; OC populations only): input data

TABLE 159. Mixed-treatment comparison – ADAS-cog at 21–16 weeks (mean change from baseline; OC populations only): results

Global

© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...